A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
A phase 3 trial testing HLX22 in gastric & gastro-oesophageal junction cancer, now recruiting.
Overview
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer is a phase 3 interventional study registered as NCT06532006, led by Shanghai Henlius Biotech with Henlius USA, and recruiting when checked on 2026-09-11. Official title: A Randomised, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer. Planned enrolment is 550 participants (estimated). The study started in 2024-11-22 and primary completion is expected in 2027-06-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shares Shanghai Henlius Biotech and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Shares Shanghai Henlius Biotech and the tag ctgov-ingest.
- TrialA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.